• A Non-Antibiotic Against Clostridium difficile Infection

A Non-Antibiotic Against Clostridium difficile Infection

A non-antibiotic drug reduces the effects Clostridium difficile infection (CDI) by disabling the bacteria’s toxins, a study showed in mice. The orally administered agent, ebselen, has been in clinical trials for an unrelated condition and could offer a new approach for combating multidrug-resistant CDI. C difficile infection causes life-threatening diarrhea and

Read more
  • Expert Panel Recommends Aspirin Therapy for Prevention of Colorectal Cancer

Expert Panel Recommends Aspirin Therapy for Prevention of Colorectal Cancer

For the first time, an expert panel has recommended aspirin therapy to prevent not only heart attacks but also colorectal cancer. The guideline for those at high risk of heart disease, published September 14 in a draft report from the US Preventive Services Task Force is the first time a major

Read more
  • Poor Adherence to Guidelines in Many Cases of Isoniazid-induced Liver Injury

Poor Adherence to Guidelines in Many Cases of Isoniazid-induced Liver Injury

Isoniazid is used to treat tuberculosis but is also a leading cause of liver injury. However, it is not clear how many cases of isoniazid-associated liver injury are reported or how many clinicians and patients adhere to American Thoracic Society (ATS) guidelines. In the September issue of Clinical Gastroenterology and Hepatology,

Read more
  • VEGF Signaling Prevents Senescence in Colorectal Tumors

VEGF Signaling Prevents Senescence in Colorectal Tumors

Vascular endothelial growth factor receptor-2 (VEGFR2) signaling prevents senescence of colorectal cancer cells by inactivating p21, researchers report in the July issue of Gastroenterology. Inactivation of this pathway correlates with survival of patients treated with anti-VEGF cancer drug bevacizumab. VEGF, a growth factor that has been well studied for its

Read more

Cheap Allergy Drug Prevents HCV Infection of Hepatocytes

An over-the-counter allergy drug may be repurposed to treat patients with hepatitis C, researchers show. Chlorcyclizine, which costs about $0.50 a tablet, could offer a low-cost alternative or addition to treatment for patients with hepatitis C virus (HCV) infection. Direct-acting antiviral therapies can cure hepatitis C, but their high cost—which

Read more
  • What’s Wrong With Herbal Supplements?

What’s Wrong With Herbal Supplements?

Herbal supplements, used by many people for weight loss and bodybuilding purposes but also to improve well-being and reduce symptoms of chronic diseases, have recently come under investigation because of uncertainty about their contents, safety, and efficacy. On February 3, the New York Times wrote that the New York State attorney general’s office accused 4 major retailers of selling

Read more
  • What is the Best Treatment Strategy for Hepatitis B?

What is the Best Treatment Strategy for Hepatitis B?

Response-guided interferon therapy is the most cost-effective first-line treatment for hepatitis B e antigen (HBeAg)-positive patients, whereas nucleos(t)ide analogues are the most cost-effective first-line therapy for HBeAg-negative patients, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Pegylated interferon and nucleos(t)ide analogues are recommended first-line treatment options for

Read more
  • A New Approach to Hepatitis B Therapy?

A New Approach to Hepatitis B Therapy?

Cyclophilins are involved in multiple steps of the hepatitis B virus (HBV) life cycle in hepatocytes—cyclophilin inhibitors reduce viral replication and HBV envelope protein production and secretion, researchers report in the February issue of Gastroenterology. The cyclophilin inhibitor alisporivir, combined with the HBV polymerase inhibitor, reduces markers of HBV infection

Read more
  • Do Selective Serotonin Reuptake Inhibitors Increase Risk for GI Bleeding?

Do Selective Serotonin Reuptake Inhibitors Increase Risk for GI Bleeding?

Use of selective serotonin reuptake inhibitors increases risk for upper gastrointestinal bleeding (UGIB) by 55%—and even more among patients also taking nonsteroidal anti-inflammatory or antiplatelet drugs, researchers report in the January issue of Clinical Gastroenterology and Hepatology. Risk might be reduced significantly by concomitant use of acid-suppressing drugs. Selective serotonin

Read more

New Programs Track Off-Label Use of Targeted Cancer Drugs

Two programs are underway to track off-label use of targeted cancer drugs and patient outcomes, as well as facilitate patient access to these agents. According to Nature News, more than 60% of US prescriptions for cancer drugs are for off-label use—often because patients have a tumor with a feature or

Read more